Social Support Is a Moderator in the Relationship Between Comorbidity Medication Adherence and Healthy Days for Patients with Metastatic Cancer

October 2016 Vol 7, No 9
Mikele Bunce, PhD, MPH
Comprehensive Health Insights, Humana, Louisville, KY; Genentech, San Francisco, CA
Adrianne W. Casebeer, PhD, MPP, MS
Comprehensive Health Insights
Dana Drzayich, Antol, MS
Comprehensive Health Insights
Sari Hopson, PhD, MSPH
Comprehensive Health Insights, Humana, Louisville, KY; Genentech, San Francisco, CA
Raya Khoury, MPH
Comprehensive Health Insights, Humana, Louisville, KY; Genentech, San Francisco, CA
Todd Michael, PharmD, RPh
Comprehensive Health Insights, Humana, Louisville, KY; Genentech, San Francisco, CA
Aparna Parikh, MD
Comprehensive Health Insights, Humana, Louisville, KY; Genentech, San Francisco, CA
Alisha Stein, RN-BC, MSN, OCN
Comprehensive Health Insights
Stephen Stemkowski, PhD, MHA
Comprehensive Health Insights, Humana, Louisville, KY; Genentech, San Francisco, CA

Objectives: Research suggests that medication adherence improves quality of life. This study explored the influence of social support (SS) on the relationship between comorbidity medication adherence (CMA) and health-related quality of life for patients with cancer.

Methods: Patients with metastatic breast, colorectal, or lung cancer undergoing cancer treatment in 2015 and at least 1 comorbid condition were mailed surveys to assess SS, CMA, and Healthy Days. The Medical Outcomes Study Social Support Survey Instrument captured patient-perceived SS. The SS scale ranges from 0 to 100 and was collapsed into 2 categories: poor/fair (<60-80) and good (>80). CMA was assessed using the 8-point Morisky Medication Adherence Scale and was collapsed into 2 categories: low (<6) and high (≥6). The Centers for Disease Control and Prevention’s Healthy Days Measure assessed self-reported health-related quality of life as the number of unhealthy days (unHD) in the past 30 days. Results were reported as mean (standard deviation); statistical significance was assessed by t test. Negative-binomial regression was used to assess the relationship between CMA and SS on unHD. Results were presented as rate ratios (95% CIs).

Results: Of 7432 patients surveyed, 25% (n = 1847) responded. Respondents were 67% female, and 88% were Medicare beneficiaries, with a mean age of 69.2 ± 9.2 years. Good SS was reported by 63% of patients; fair/poor SS by 37% of patients. High CMA was reported in 70% of the cohort, and low CMA in 30%. The average number of unHD was 14.0 ± 11.9. Regression analysis revealed the association between CMA and unHD was moderated by SS. In a main effects regression model, low CMA (1.18 [1.03, 1.35]; P = .0155), but not low SS (1.12 [0.99, 1.27]; P = .0694), was associated with unHD. When tested for a moderator effect, unHD was regressed on CMA/SS interaction along with main effects. Evidence of moderation was observed in the interaction between SS and CMA (P = .0393) and no association with unHD by SS (P = .6819) or CMA (P = .5895). With low SS, low CMA increased unHD by 33% (1.33 [1.01-1.74]), whereas with high SS, low CMA increased unHD by only 5% (1.05 [0.88, 1.2]).

Conclusions: Patients with low CMA experienced more unHD than those with high CMA. The increase in unHD attributed to low CMA is further amplified by low SS. This finding suggests that a greater importance should be placed on patients’ social and caregiver resources.

Note: This work was supported by Genentech, Inc.

Related Articles
Assessment of Side Effects (SEs) Impacting Quality of Life (QOL) in Patients (Pts) Undergoing Treatment (tx) for Advanced Breast Cancer (ABC) in Clinical Practice: A Real-World (RW) Multicountry Survey
November 2022 Vol 13, No 11
To examine how SEs impacting QOL in pts with ABC are perceived.
Intracranial Activity of Tepotinib in Patients with MET Exon 14 (METex14) Skipping Non–Small-Cell Lung Cancer (NSCLC) Enrolled in VISION
November 2022 Vol 13, No 11
To provide analysis of the intracranial activity of tepotinib in patients with METex14 skipping NSCLC with BM from the VISION study to aid oncology nurse navigators who manage this population of patients.
MOMENTUM: Phase 3 Randomized Study of Momelotinib (MMB) versus Danazol (DAN) in Symptomatic and Anemic Myelofibrosis (MF) Patients Previously Treated with a JAK Inhibitor
November 2022 Vol 13, No 11
MF is a rare bone marrow cancer characterized by fibrosis, abnormal blood cell production, and dysregulated JAK/STAT signaling.1,2
Last modified: August 10, 2023

Subscribe Today!

To sign up for our print publication or e-newsletter, please enter your contact information below.

I'd like to receive:

  • First Name *
    Last Name *
     
     
    Profession or Role
    Primary Specialty or Disease State
    Country